Incanthera PLC - AGM 2021 - COVID Update
RNS Number : 6872B
Incanthera PLC
14 June 2021



            14 June 2021

Incanthera plc


("Incanthera" or the "Company")


Annual General Meeting 2021


COVID Update


Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, announces an update to the current Annual General Meeting ("AGM") arrangements, as announced on 19 May 2021.


Incanthera's AGM is currently due to be held at the offices of Gateley Plc, Ship Canal House, 98 King Street, Manchester, M2 4WU at 11:00 a.m. on Wednesday, 23 June 2021.


Announcements made by the Government this week, have identified Greater Manchester as an area of concern relating to increasing cases of the COVID-19 Delta variant, and as such travel in or out of the identified area is discouraged.


Accordingly, the meeting location to host the minimum attendance necessary to form a quorum (which will be facilitated by the Company) has been moved from the Greater Manchester area to the Marriott Hotel, Breadsall Priory, Derby.

The Meeting will focus on the formal business of the meeting only.

Legislation and government guidance in the United Kingdom continues to place restrictions on public gatherings and we have previously advised that Shareholders are not encouraged to attend the meeting in person. Given the recent new advice on rising cases, and unnecessary travel, the health and safety of our Shareholders remains a priority. Accordingly, we regretfully advise that although we have moved the location of the AGM, we are still advising shareholders not  to attend the meeting in person.

All other details as advised in the Notice of AGM, posted to Shareholders on 19 May, remain as follows:

In order to ensure that shareholders are able to follow the proceedings of the AGM, the Company will provide access online through the Investor Meet Company platform.  However, shareholders will not be able to vote online during the Meeting and are therefore urged to submit their votes via proxy, if they have not already done so, as early as possible, electronically or by post.

These documents are also available, in electronic form, for download on the Company's website: 

Shareholders are also invited to submit written questions for the Board to consider. Questions can be pre submitted in advance of the AGM via the Investor Meet Company Platform up to 9.00 a.m. on 22 June 2021, being the day before the AGM, or via the Investor Meet Platform at any time during the AGM itself.

The Board will respond to key questions during the meeting and will provide such answers on its website thereafter. 

Shareholders who wish to attend the AGM online should register for the event in advance via the following link: 


The Board would like to take this opportunity to thank Shareholders for their understanding and support of the necessary precautions taken during this time.



For further enquiries:


Incanthera plc


Tim McCarthy, Chairman


Simon Ward, Chief Executive Officer


Suzanne Brocks, Head of Communications




+44 (0) 7831 675747



+44 (0) 7747 625506



+44 (0) 7776 234600



Aquis Exchange Corporate Adviser: 

Cairn Financial Advisers LLP

Jo Turner/James Lewis

+44 (0) 20 7213 0880




Stanford Capital Partners Ltd

Patrick Claridge/John Howes/Bob Pountney

+44 (0) 20 3815 8880


Notes to Editors


Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.


The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.


The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions. 


Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.


For more information on the Company please visit:




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.